Phyton Biotech Achieves Manufacturing Milestone with Thapsigargin, the Active Agent in Mipsagargin

Phyton Biotech Achieves Manufacturing Milestone with Thapsigargin, the Active Agent in Mipsagargin


This milestone signifies the advancement in Phyton's Plant Cell Fermentation development program that now has begun to define the process by which the Thapsia plant is converted into a preserved, fermentable cell line, thus providing a more sustainable source of high-quality thapsigargin. Phyton is converting the Thapsia plant into thapsigargin in partnership with Inspyr Therapeutics, Inc. , a clinical-stage biotechnology company that has a patented technology platform utilizing thapsigargin for its prodrug delivery system, mipsagargin.



from Biotech News